China Publishes World's First In-Vivo CAR-T Human Trial in The Lancet

Imagine receiving a cancer treatment that requires just one injection instead of weeks of hospitalization. That’s the promise of in-vivo CAR-T therapy, and Chinese researchers have just published the world’s first human clinical evidence in The Lancet, one of medicine’s most prestigious journals.

The study, published on July 19, 2025 (electronically available July 3, 2025), represents a paradigm shift in how we approach CAR-T cell therapy for blood cancers. Led by researchers at Wuhan Union Hospital, affiliated with Huazhong University of Science and Technology, this breakthrough could dramatically simplify cancer immunotherapy and make it accessible to far more patients worldwide.

What is In-Vivo CAR-T Therapy?

Traditional CAR-T therapy has revolutionized treatment for certain blood cancers, but it comes with significant challenges. The conventional approach requires extracting a patient’s T-cells, genetically modifying them in a specialized laboratory over 2-3 weeks, and then infusing them back into the patient. This process costs hundreds of thousands of dollars and is only available at specialized cancer centers.

In-vivo CAR-T therapy eliminates the need for ex vivo cell manipulation. Instead of removing T-cells from the body, genetic modification happens directly inside the patient’s bloodstream using specially engineered viral vectors. This approach could reduce manufacturing time from weeks to hours and potentially lower costs by 80-90%.

The Wuhan team targeted BCMA (B-cell maturation antigen), a protein highly expressed on multiple myeloma cells. By engineering lentiviral vectors to deliver CAR genes directly to circulating T-cells, they achieved what many considered impossible: functional CAR-T cells generated inside the human body.

The Lancet Published Breakthrough

The study, titled “In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma,” represents a landmark in oncology research. The research team was led by Professor Heng Mei from the Institute of Hematology at Wuhan Union Hospital, in collaboration with EsoBiotec (Belgium) and Shenzhen Pregene Biopharma.

Key publication details:

• Journal: The Lancet
• Publication Date: July 19, 2025 (electronic: July 3, 2025)
• DOI: 10.1016/S0140-6736(25)01030-X
• PMID: 40617243
• Study Type: Case series

The research received funding from the National Natural Science Foundation of China (grants 82425003, 82350103, and 82330005), highlighting the country’s strategic investment in cutting-edge cancer immunotherapy.

How It Works: From Weeks to Hours

The technical innovation centers on engineered lentiviral vectors that can specifically target and transduce T-cells in circulation. Unlike traditional approaches that require leukapheresis, clean-room manufacturing, and lymphodepleting chemotherapy, the in-vivo approach uses a streamlined protocol:

The Process:

1. Vector Administration: A single intravenous infusion delivers the engineered lentiviral vector
2. In-Situ Transduction: The vector homes to circulating T-cells and delivers the CAR gene
3. Endogenous Expansion: The patient’s body produces functional CAR-T cells naturally
4. Tumor Targeting: Newly created CAR-T cells seek and destroy myeloma cells expressing BCMA

This approach eliminates the need for specialized manufacturing facilities, potentially making CAR-T therapy available at any hospital capable of administering intravenous infusions. The technology was developed through a collaboration between Chinese academic researchers and Belgian biotech company EsoBiotec, with manufacturing support from Shenzhen Pregene Biopharma.

Clinical Implications and Future Directions

The successful publication in The Lancet validates the safety and feasibility of in-vivo CAR-T therapy in humans. While this initial report focuses on demonstrating the approach works, larger clinical trials are needed to fully characterize efficacy and long-term outcomes.

Potential advantages of in-vivo CAR-T:

• Reduced manufacturing complexity: No need for cell extraction or laboratory manipulation
• Faster treatment initiation: Weeks reduced to hours
• Lower costs: Eliminating specialized manufacturing could dramatically reduce treatment costs
• Increased accessibility: Could bring CAR-T therapy to regions without advanced manufacturing infrastructure
• Reduced patient burden: Fewer hospital visits and shorter treatment duration

However, researchers caution that challenges remain. Precise control over CAR-T cell expansion, managing potential toxicities like cytokine release syndrome (CRS), and ensuring consistent vector delivery all require further investigation. The technology also raises questions about manufacturing scalability and regulatory pathways for in-vivo gene therapies.

For international patients considering CAR-T therapy, this breakthrough suggests a future where treatment may become faster, less expensive, and more widely available. Wuhan Union Hospital, as a leading tertiary care center in central China, continues to advance innovative cancer therapies and may represent an option for patients seeking cutting-edge treatment.

Conclusion

The publication of the first human in-vivo CAR-T trial in The Lancet marks a historic milestone in cancer immunotherapy. Chinese researchers have demonstrated that it is possible to generate functional CAR-T cells directly inside the human body, potentially transforming a complex, weeks-long process into a simple injection.

While larger trials are needed to confirm efficacy and safety, this proof-of-concept study opens the door to democratizing CAR-T therapy. For patients with relapsed or refractory multiple myeloma who previously faced limited options, this innovation offers hope for faster, more accessible, and potentially more affordable treatment.

As in-vivo CAR-T technology matures, it could reshape the landscape of cancer immunotherapy, bringing curative potential to patients worldwide regardless of their proximity to specialized manufacturing centers. China’s strategic investment in this technology, evidenced by substantial National Natural Science Foundation funding, positions the country as a leader in next-generation cancer therapeutics.

Sources

1. Xu J, Liu L, Parone P, et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. The Lancet. 2025;406(10500):228-231. DOI: 10.1016/S0140-6736(25)01030-X
2. PubMed. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. PMID: 40617243
3. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan, China.
4. EsoBiotec. Immune-shielding lentiviral vectors for in-vivo CAR-T therapy. Mont-Saint-Guibert, Belgium.
5. Shenzhen Pregene Biopharma. CAR-T cell therapy development. Shenzhen, China.
6. National Natural Science Foundation of China. Grant numbers 82425003, 82350103, 82330005.